In this trial of patients with aneurysmal subarachnoid hemorrhage, they were randomized to IV magnesium versus placebo, for 10 days followed by a taper (with a goal level 2-2.5 mmol/L). Delayed ischemic infarction occurred significantly less in the magnesium group (22% vs 51%, assessed by CT), as did vasospasm (67% vs 85%, assessed by USG). This relatively simple and inexpensive intervention holds promise for patients with SAH (abstract)
Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.